Trial Profile
A Randomized, Double-Blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 2 Infection (ENDURANCE-2)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Glecaprevir/pibrentasvir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms ENDURANCE-2
- Sponsors AbbVie
- 28 Mar 2019 Results assessing the efficacy and safety of Glecaprevir/Pibrentasvir treatment for 8-16 weeks from 9 Phase II and Phase III trials (NCT02243280, NCT02243293, NCT02604017, NCT02640482, NCT02640157, NCT02636595, NCT02642432, NCT02651194, and NCT02446717) published in the Clinical Infectious Diseases.
- 01 Dec 2018 Results of a pooled post-hoc analysis from ENDURANCE-1, 2, 3, 4, 5 studies, published in the Infectious Diseases and Therapy
- 30 Jul 2018 Results of pooled data from 8 studies (SURVEYOR-1, 2, ENDURANCE-1, 2, 3, 4, and EXPEDITION-1, 4), were published in the Antimicrobial Agents and Chemotherapy.